NFKB1 and prostate cancer: In the C vs. NP comparison, cancer signaling pathways such as NFKB, HIF1, and apoptosis signaling pathways, and prostate cancer, colorectal cancer, endometrial cancer, non-small cell lung cancer, renal cell carcinoma, glioma, and acute myeloid leukemia were significantly enriched.